Angiotensin II type 2 receptor (AT2R) is associated with increased tolerance of the hyperthyroid heart to ischemia-reperfusion

Cardiovascular Drugs and Therapy

Volumn 27, Issue 5, 2013, Pages 393-402

  Tavares, Felix Meira ^a   Da Silva, Ivson Bezerra ^a   Gomes, Dayane Aparecida ^a   Barreto Chaves, Maria Luiza Morais ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardioprotection; Ischemia; Reperfusion; Thyroid hormone; Type 2 angiotensin II receptor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIOTHYRONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTHYROIDISM; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; CARDIOMEGALY; HYPERTHYROIDISM; IMIDAZOLES; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; THYROXINE; TRIIODOTHYRONINE; VENTRICULAR PRESSURE;

EID: 84885182317     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6473-x     Document Type: Article

References (46)

1. Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev. 2010;15:125-32.
2. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31-50.
3. Kahaly GJ, Dillmann WH. Tyroid hormone action in the heart. Endocr Rev. 2005;26:704-28.
4. Klein I, Ojamaa K. Thyroid hormone: targeting the vascular smooth muscle cell. Circ Res. 2001;88:260-1.
5. Buser PT, Wikman-Coffelt J, Wu ST, Derugin N, Parmley WW, Higgins CB. Postischaemic recovery of mechanical performance and energy metabolism in the presence of left ventricular hypertrophy. A 31P-MRS study. Circ Res. 1990;66:735-46.
6. Pantos C, Mourouzis I, Tzeis S, et al. Propranolol diminishes cardiac hypertrophy but does not abolish acceleration of the ischaemic contracture in hyperthyroid hearts. J Cardiovasc Pharmacol. 2000;36:384-9.
7. Venditti P, Masullo P, Agnisola C, Di Meo S. Effect of vitamin E on the response to ischaemia-reperfusion of Langendorff heart preparations from hyperthyroid rats. Life Sci. 2000;66:697-708.
8. Pantos C, Malliopoulou V, Mourouzis I, et al. Long-term thyroxine administration protects the heart in a similar pattern as ischaemic preconditioning. Thyroid. 2002;12:325-9.
9. Pantos C, Malliopoulou V, Paizis I, et al. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem. 2003;242:173-80.
10. Sirlak M, Yazicoglu L, Inan MB, et al. Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg. 2004;26:720-5.
11. Pantos C, Malliopoulou V, Varonos DD, Cokkinos DV. Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol. 2004;99:101-20.
12. Barreto-Chaves ML, Carrillo-Sepúlveda MA, Carneiro-Ramos MS, Gomes DA, Diniz GP. The crosstalk between thyroid hormones and the renin-angiotensin system. Vascul Pharmacol. 2010;52:166-70.
13. Hu LW, Benvenutti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1473-80.
14. Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway. Basic Res Cardiol. 2009;104:653-67.
15. Carneiro-Ramos MS, Diniz GP, Nadu AP, et al. Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol. 2010;105:325-35.
16. De Gasparato M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-72.
17. Gross V, Obst M, Luft FC. Insights into angiotensin II receptor function through AT2 receptor knockout mice. Acta Physiol Scand. 2004;181:487-94.
18. Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens. 2010;28:S50-5.
19. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1-6.
20. Yang BC, Phillips MI, Zhang YC, et al. Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA. Circ Res. 1998;83:552-9.
21. Xu Y, Kumar D, Dyck JR, Ford WR, Clanachan AS, Lopaschuk GD, et al. AT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol Heart Circ Physiol. 2002;282:H1206-15.
22. Przyklenk K, Kloner RA. "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol. 1993;88 Suppl 1:139-54.
23. Pantos C, Paizis I, Mourouzis I, et al. Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning. Horm Metab Res. 2005;37:500-4.
24. Langendorff O. Untersuchungen an uberlebenden Saugethierherzen. Pflügers Arch. 1895;61:291-332.
25. Fallen EL, Elliot WC, Gorlin R. Apparatus for study of ventricular function and metabolism in the isolated perfused rat heart. J Appl Physiol. 1967;22:836-9.
26. Carrillo-Sepulveda MA, Ceravolo GS, Furstenau CR, et al. Emerging role of angiotensin type 2 receptor (AT2R) /Akt/ NO pathway in vascular smooth muscle cell in the hyperthyroidism. PLoS One. 2013;8:e61982.
27. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;9:1926-35.
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
29. Opie LH. Cardioprotection at a distance - remote conditioning takes the stage. Exp Physiol. 2012;97:905.
30. Pantos C, Malliopoulou V, Mourouzis I, et al. Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res. 2006;38:308-13.
31. Barreto-Chaves ML, de Souza MP, Fürstenau CR. Acute actions of thyroid hormone on blood vessel biochemistry and physiology. Curr Opin Endocrinol Diabetes Obes. 2011;18:300-3.
32. Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML. Angiotensin type 1 (AT1) and type 2 (AT2) receptors mediate the increase in TGF-B1 in thyroid hormone-induced cardiac hypertrophy. Pflugers Arch - Eur J Physiol. 2007;454:75-81.
33. Murphy TJ, Takeuchi K, Alexander RW. Molecular cloning of AT1 angiotensin receptors. Am J Hypertens. 1992;5:236S-42.
34. Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543-6.
35. Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest. 1996;97:1978-82.
36. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1999;31:349-55.
37. Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation. 2004;109:2296-301.
38. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-35.
39. Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics. 2000;2:13-20.
40. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension. 2003;42:600-4.
41. Hermann R, Marina Prendes MG, Torresin ME, Vélez D, Savino EA, Varela A. Effects of the AMP-activated protein kinase inhibitor compound C on the postconditioned rat heart. J Physiol Sci. 2012;62:333-41.
42. Thuc LC, Teshima Y, Takahashi N, et al. Cardioprotective effects of pravastatin against lethal ventricular arrhythmias induced by reperfusion in the rat heart. Circ J. 2011;75:1601-8.
43. Oishi Y, Ozono R, Yano Y, et al. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension. 2003;41:814-8.
44. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57:696-705.
45. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104:403-11.
46. Olson AK, Bouchard B, Ning XH, Isern M, Rosiers CD, Portman MA. Triodothironine increases myocardial function and pyruvate entry into the citric acid cycle after reperfusion in a model of infant cardiopulmonary bypass. Am J Physiol Heart Circ Physiol. 2012;302:H1086-93.